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Summary of main points: Researchers are preparing for human challenge trials with emerging
SARS-CoV-2 variants. We argue that these trials can be conducted ethically.
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Abstract
The world’s first COVID-19 human challenge trial using the D614G strain of SARS-CoV-2 is
underway in the United Kingdom. The Wellcome Trust is funding challenge stock preparation of
the Beta variant (B.1.351) for a follow-up human challenge trial, and researchers at Imperial
College London are considering conducting that trial. However, little has been written thus far
about the ethical justifiability of human challenge trials with SARS-CoV-2 variants of concern.
While vaccine resistance as such does not increase risks for volunteers in COVID-19 challenge
trials, we explore two specific characteristics of some variants that may initially be thought to
make such trials unethical and conclude that SARS-CoV-2 variant challenge trials can remain
ethical.
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Background
While the authorization of several highly effective vaccines has significantly reduced cases of
COVID-19 in some countries, virus variants that may evade authorized vaccines threaten to
reverse progress [1].
The Beta and Delta variants are of particular concern. While the CDC [2] reports that “currently
authorized mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) provide protection
against ... [the Beta variant],” other vaccines which represent the majority of the pre-purchased
COVID-19 vaccine doses [3], as well as doses ordered by COVAX [4], show reduced efficacy
against this variant.
Interim analysis of Janssen’s Phase III trial found that vaccine efficacy in South Africa was
reduced to 57% post-vaccination [5]. A Phase IIb trial from Novavax found that their vaccine
efficacy against the Beta variant was just 49% [6]. An AstraZeneca study [7] of 2,000 people in
South Africa found that “vaccine efficacy against this variant, analyzed as a secondary end point,
was 10.4%.” This is particularly worrisome, since the AstraZeneca vaccine is the most widely
purchased in the world. The African Union has already bought 500,000,000 doses, and South
Africa, where the Beta variant is dominant, has had to sell their entire portfolio [8].
The WHO warns that the Delta variant is becoming the dominant strain of SARS-CoV-2
worldwide due to its increased transmissibility [9]. While the Pfizer vaccine remains highly
protective against the Delta variant [10], a recent UK analysis found that a single vaccine dose is
35% less effective against the Delta variant than the Alpha variant [11].
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The FDA recognizes that the emergence of vaccine-resistant strains warrants immediate
preparation of strain-specific booster doses from all authorized vaccine candidates [12]. As a
matter of basic preparation, this Perspective adds, the 3-4 month long process of developing
challenge stock for all variants that may be vaccine resistant, including both the Delta and
Gamma variants, should begin immediately. Commentators skeptical of approving any COVID
challenge trial nonetheless proposed laying the groundwork for these trials immediately [13], and
their proposal is especially sensible for variant challenges. Given the immense humanitarian
benefits of authorizing vaccines that fight a pandemic just weeks or days earlier, the modest cost
of viral preparation under Good Manufacturing Practices for human challenge trials is well worth
the chance that the challenge stocks are never used.
The limits of conventional studies for variant-specific
vaccine boosters
Immunogenicity studies that demonstrate adequate levels of neutralizing antibodies against
variants of concern may be indicative of booster efficacy, per regulatory guidance in the United
States [12] and Europe [14]. However, these studies face two important limitations. First, while
some data show that neutralizing antibodies are predictive of protection against SARS-CoV-2
infection [15], this may not be the case for the Beta variant and future variants markedly more
resistant to neutralization [16]. Stronger data describing which immune responses correlate with
protection against these variants would facilitate determining the efficacy of boosters by
surrogate endpoint. Second, a disadvantage of relying solely on immunogenicity studies to infer
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booster efficacy is that no data can be gathered from them on viral shedding and viral activity in
the upper respiratory tract [17], significantly narrowing information gathered on viral
transmission post-vaccination.
Conventional clinical efficacy trials for boosters also face limitations. First, because efficacy
studies require a critical mass of trial participants to encounter a specific strain of the virus, these
trials may not produce efficacy results if a different strain predominates in the population during
the trial. Second, the strain that predominates in the trial population cannot be reliably predicted
in advance of actually conducting the lengthy trial. Third, subdued case rates may cause these
trials to take many months, costing lives in the meantime. Fourth, vaccination from a placebo
group in a large, non-isolated randomized controlled trial during an epidemic is ethically fraught
[18].
The role of human challenge trials with SARS-CoV-2
variants
The UK Medicines & Healthcare products Regulatory Agency (MHRA) and the European
Medical Authority (EMA) have both stated that human challenge trials can deliver important
evidence about the effect of updated vaccine candidates on variants of concern [17, 19]. The
Wellcome Trust has begun funding preparation of the Beta variant challenge stock for a variant
challenge model [20], and researchers at Imperial College London are considering conducting a
Beta variant challenge trial [21]. Notably, the vaccine resistance of a given variant does not
imply that it is more virulent or transmissible, and therefore vaccine resistance as such does not
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increase risk for challenge volunteers when compared to ongoing characterization studies, in
which volunteers are exposed to the challenge agent without first receiving a vaccine. Later, we
dedicate a specific discussion to the greater virulence and transmissibility of relevant variants
that may be used in challenge trials, and argue that these trials can remain ethical.
Challenge trials can assist in discerning a correlate of protection against different variants of
SARS-CoV-2 by investigating the relationship between neutralizing antibody titers presumably
caused by efficacious vaccination and a variant challenge [22, 23]. The more evidence that is
gathered to establish a robust correlate, the more likely it is that boosters for vaccines can be
authorized by surrogate endpoint, accelerating the path to market for boosters that are in early
stages of development. Challenge trials could also be used to determine the extent to which
subjects who were infected with earlier strains of SARS-CoV-2 can be reinfected with newer
variants.
More broadly, challenge trials could offer unprecedented detail regarding viral kinetics and the
immune response to variants such as the Beta strain. To quote the UK MHRA guidance on
challenge studies for SARS-CoV-2 variants [17], “human challenge studies have the advantage
that the course of developing immunity, viral shedding, local suppression of SARS-CoV-2
shedding in the upper respiratory tract and other parameters can be measured in a controlled
setting.”
Once a variant challenge stock is prepared, vaccine efficacy in terms of curbing infection and
infectiousness can be tested more rapidly in a challenge trial than a field trial. Su et al. have
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outlined a plan to assess the efficacy of authorized and updated vaccines against SARS-CoV-2
variants [24]. If unvaccinated volunteers are needed for such a trial but are difficult to find in the
UK, trialists can open recruitment from other countries with lower vaccination rates.
In sum, human challenge studies could provide data on variant boosters’ efficacy in curbing
infection rates, accelerate the discernment of a correlate of protection against virus variants, and
advance our understanding of variant pathogenesis.
Human challenge trials against SARS-CoV-2 variants
can remain ethical
Human challenge trials involving variants that evade authorized vaccine protection such as the
Beta variant could have momentous global public health value, yet little is written about their
specific ethics.
The ethical justifiability of COVID-19 human challenge trials with the D614G mutation strain
has been endorsed by the World Health Organization [25] and the UK MHRA [17]. As we have
argued elsewhere, the risks to the young, healthy volunteers in COVID-19 human challenge trials
are far lower than the medical risks of some commonly accepted living organ donations, and the
expected global public health value of these trials is dramatically higher [26].
However, a human challenge trial with SARS-CoV-2 variants would raise unique ethical
considerations. Here we explore two that may initially motivate opposition—some variants’
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greater transmissibility and virulence— and argue that while the trials’ risk-reward ratio will
depend on the exact strain and type of trial, some vaccine-resistant variant challenge trials can be
ethically justified.
Transmissibility
The Alpha, Beta, and Delta variants appear around 50% more transmissible than the strain first
identified in Wuhan [27]. However, increased transmissibility, as such, does not directly increase
the risks to human challenge participants. What it may do is increase the social value of that
challenge trial, which speeds the authorization of a vaccine or booster against a more
transmissible and hence, for society, more dangerous, variant.
Greater transmissibility does underline the importance of biosafe quarantine facilities to ensure
that infected volunteers do not inadvertently cause community infection. The WHO Working
Group has outlined specific standards for biosecure facilities to prevent such transmission [28],
and those are already part of operations for challenge trials planned at Imperial College and
Oxford University.
Virulence
Limited evidence suggests that the Beta variant is more lethal than the strain first identified in
Wuhan [29]. However, a recent study of seven EU countries by Funk et al. found “3.5–3.6 times
higher odds of hospitalisation for age groups 40–59” due to the Beta variant. Their analysis did
not show increased risk of death from the Beta variant [30].
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Since the risks of a severe adverse events in a COVID-19 human challenge trial are already very
low— Manheim et al. find that the risk of death for a trial participant is around 0.00025% [31]
— a threefold increase in risks for a Beta variant challenge volunteer would remain far lower
than common comparator risks like right liver lobe donation, which involves a 0.4% risk of death
and a 1.1% risk of lasting disability [32]. The threefold greater risk for young healthy volunteers
would also remain well within postulated upper bounds of risk in clinical trials, such as the 1%
cap on risk of severe adverse events [33], a standard echoed by critics of challenge trials [34]. If
challenge volunteers are vaccinated before the trial, risks will be reduced considerably. To reduce
risks further, researchers can also use low-dosage challenge trials with virus variants [35].
Response to Objections
Objection 1: Variant challenge study data may become irrelevant
should a further strain become dominant.
It might seem that newer virus variants might rapidly overtake one another, reducing the
usefulness of the data from challenge trials of formerly predominant variants. However, the risks
of waiting so long that study data becomes irrelevant are greater in field studies than challenge
studies. The reason is that field studies require a critical mass of trial participants to be exposed
to a particular variant. Researchers should prepare challenge stock for each potentially
vaccine-resistant strain expeditiously, given the reasonable cost of investment and the reasonable
chance that one variant still predominates by the time the data of a challenge trial is reported.
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Objection 2: Challenge trials do not produce generalizable
efficacy data because ethically, only young, healthy volunteers
can participate.
One objection to variant challenge trials is that the resultant data in young, healthy volunteers are
unrepresentative of the broader population, which include those at higher risk of medical
complications. However, it is not clear that to authorize a vaccine booster we need to verify all
effects of a vaccine in all population groups [36]. Even if challenge trial data is insufficient for
authorization on its own, the data can still be used in a fast-to-fail approach in which the most
promising vaccines are selected for optimized investment. Most importantly, though, challenge
trial data may be generalized by discerning the correlates of protection and conducting a rapid
and safe immune bridging study in any population group of interest [37].
Objection 3: Challenge trials with new variants can jeopardize
public trust.
Some have argued that any COVID-19 human challenge trials would spread distrust in the
research process and undermine vaccine confidence [38]. This risk may seem higher in variant
challenges. However, the best available evidence on public perceptions on COVID-19 challenge
trials and public trust— an international survey of nearly 6,000 respondents— found strong
support for challenge testing across all demographic groups [39]. The UK, which is the only
country to run COVID-19 challenge trials, has higher vaccine confidence than the US and the
10
PREPRINT — CHALLENGE TRIALS WITH SARS-COV-2 VARIANTS — AR & NE
rest of Europe [40], and that confidence has not dropped since rival challenges were approved
and launched.
Conclusion
The Beta SARS-CoV-2 variant, and future vaccine-resistant virus variants, threaten to get us
back to square one in the fight against the pandemic. Human challenge trials can accelerate the
authorization of vaccine boosters and advance our understanding of these variants. While the
risk-reward ratio of each trial will depend on the variant and study design, these trials can remain
ethical, and researchers should begin preparations for them immediately.
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